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Abstract
Purpose:  To  determine  the  combined  effect  of  TheraTears® Lubricant  Eye  Drops,  TheraTears®
SteriLid  Eyelid  Cleanser,  and  TheraTears® Nutrition  on  dry  eye  signs  and  symptoms.
Methods:  This  prospective  study  enrolled  28  dry  eye  participants.  Participants  were  instructed
to use  the  Lubricant  Eye  Drops  at  least  2--4×  a  day,  SteriLid  1--2×  a  day,  and  Nutrition  3  gel  caps
once a  day.  Participants  were  followed  up  at  baseline,  1  month  and  3  months.  Outcome  variables
were the  Ocular  Surface  Disease  Index  (OSDI),  Symptom  Assessment  iN  Dry  Eye  (SANDE)  ques-
tionnaire, non-invasive  tear  break-up  time  (NIBUT),  osmolarity,  number  of  meibomian  glands
blocked (#MG  blocked),  meibum  quality,  eyelid  margin  features,  Schirmer’s  test,  tear  ﬁlm  lipid
layer thickness  (LLT),  meniscus  height,  corneal  and  conjunctival  staining.
Results:  Twenty  participants  (mean  age  =  43,  from  23  to  66,  17F,  3M)  completed  the  study.
Participants  reported  having  used,  on  average,  the  Lubricant  Eye  Drop  2.4×/day,  the  Ster-
iLid 1.1×/day,  and  the  Nutrition  3  gel  caps  1×/day.  There  was  a  signiﬁcant  change  over  time
(p <  0.05)  for  OSDI  (−21.2  points),  SANDE  (−32.4  points),  NIBUT  (+0.43  s),  eyelid  margin  features
(−1.1 grade),  meibum  quality  (−1.0  grade),  and  #MG  blocked  (−4.0  glands).
Conclusion:  By  using  a  combination  of  TheraTears® Lubricant  Eye  Drop,  SteriLid,  and  Nutrition,
patients experience  signiﬁcant  relief  in  both  dry  eye  symptoms  and  signs.
© 2016  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).∗ Corresponding author at: Centre for Contact Lens Research, University of Waterloo School of Optometry & Vision Science Waterloo,
ntario, Canada N2L 3G1.
E-mail address: wngo@uwaterloo.ca (W.  Ngo).
ttp://dx.doi.org/10.1016/j.optom.2016.05.001
888-4296/© 2016 Spanish General Council of Optometry. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Alivio  de  los  síntomas  y  signos  del  ojo  seco  con  el  uso  de  una  combinación  de
lubricantes,  productos  para  higiene  palpebral  y  nutracéuticos  oculares
Resumen
Objetivo:  Determinar  el  efecto  combinado  de  las  gotas  lubricantes  TheraTears®,  el  limpiador
palpebral  TheraTears®  SteriLid,  y  TheraTears®  Nutrition  sobre  los  signos  y  síntomas  del  ojo
seco.
Métodos:  Este  estudio  prospectivo  incluyó  a  veintiocho  participantes  con  ojo  seco,  a  quienes
se solicitó  que  utilizaran  las  gotas  lubricantes  al  menos  2-4  veces  al  día,  SteriLid  1-2  veces  al
día, y  las  cápsulas  Nutrition  3  gel  una  vez  al  día.  Se  realizó  un  seguimiento  al  inicio,  al  cabo
de un  mes,  y  a  los  tres  meses.  Las  variables  de  los  resultados  fueron  OSDI  (Ocular  Surface
Disease  Index),  el  cuestionario  SANDE  (Symptom  Assessment  iN  Dry  Eye),  NIBUT  (non-invasive
tear break-up  time),  la  osmolaridad,  el  número  de  glándulas  de  Meibomio  bloqueadas  (#MG
bloqueadas),  la  calidad  de  la  secreción  de  las  glándulas  de  meibomio,  las  características  del
margen palpebral,  la  prueba  de  Schirmer,  LLT  (grosor  de  la  capa  lipídica)  de  la  película  lagrimal,
altura del  menisco,  y  tinción  de  la  córnea  y  la  conjuntiva.
Resultados:  Veinte  participantes  (edad  media  =  43,  de  23  a  66,  17M,  3V)  completaron  el  estu-
dio. Los  participantes  reportaron  que  habían  utilizado,  de  media,  las  gotas  lubricantes  2,4
veces/día,  SteriLid  1,1  veces/día,  y  las  cápsulas  Nutrition  3  gel  1  veces/día.  No  se  produjo  un
cambio signiﬁcativo  a  lo  largo  del  tiempo  (p  <  0,05)  en  cuanto  a  OSDI  (-21,2  puntos),  SANDE
(-32,4 puntos),  NIBUT  (+0,43s),  características  del  margen  palpebral  (-1,1  grado),  calidad  de  la
secreción  de  las  glándulas  de  meibomio  (-1,0  grado),  y  #MG  bloqueadas  (-4,0  glándulas).
Conclusión:  Con  el  uso  de  una  combinación  de  gotas  lubricantes,  SteriLid,  y  Nutrition,  de
TheraTears®,  los  pacientes  experimentan  un  alivio  signiﬁcativo  de  los  síntomas  y  signos  del
ojo seco.
©  2016  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Dry  eye  is  a  complex  multifactorial  condition  that  was
deﬁned  by  the  2007  Dry  Eye  Workshop  as:
‘‘Dry  eye  is  a  multifactorial  disease  of  the  tears  and
ocular  surface  that  results  in  symptoms  of  discomfort,
visual  disturbance,  and  tear  ﬁlm  instability  with  poten-
tial  damage  to  the  ocular  surface.  It  is  accompanied  by
increased  osmolarity  of  the  tear  ﬁlm  and  inﬂammation
of  the  ocular  surface’’.1
The  two  major  etiological  categories  of  dry  eye  are  aque-
ous  deﬁcient  and  evaporative  dry  eye.1 The  former  consists
of  a  wide  variety  of  conditions  that  result  in  a  deﬁciency
of  the  aqueous  portion  of  tears  (e.g.  typical  aqueous  deﬁ-
cient  dry  eye  and  Sjögren’s  syndrome).1 The  latter  category
includes  a  group  of  tear  ﬁlm  and  adnexa  anomalies  that
quicken  the  evaporative  loss  of  tears  from  the  surface  of
the  eye  (e.g.  meibomian  oil  deﬁciency).1
In  either  case,  the  symptoms  brought  about  by  ocular
dryness  can  severely  affect  quality  of  life.2--4 Individuals  suf-
fering  from  dry  eye  may  feel  signiﬁcant  discomfort  during
certain  tasks,  including  driving,  reading,  computer  usage,
or  simply  being  in  an  environment  with  low  humidity.2The  clinical  assessment  of  dry  eye  typically  include
tests  that  assess  subjective  symptoms,  along  with  vari-
ous  features  of  the  ocular  surface,  adnexa  and  accessory
tear  glands.5 The  assessment  of  symptoms  is  conducted
r
t
m
phrough  symptom  questionnaires,5 with  some  assessing
urely  symptoms,6,7 and  others  combining  symptoms  with
uality  of  life  measures.8,9 The  physical  signs  of  dry  eye
re  commonly  assessed  with  corneal  staining,  conjunctival
taining,  tear  breakup  time,  meibomian  gland  (MG)  func-
ion,  and  by  undertaking  a  Schirmer’s  test.5 These  clinical
ests  permit  determination  of  the  extent  of  the  condition,
long  with  monitoring  any  improvement  of  symptoms  and
igns  with  the  administration  of  dry  eye  treatment.5
The  management  of  dry  eye  disease  is  complex,
ulti-interventional  and  commonly  involves  using  tear
upplementation,10 eyelid  hygiene,11 and  omega-3  essential
atty  acids.10 Artiﬁcial  tear  supplements,  which  vary  widely
n  their  composition,  serve  to  keep  the  ocular  surface  lubri-
ated  and  help  relieve  patient  discomfort.10 Eyelid  hygiene,
f  which  many  variations  exist,12--14 removes  bacteria  from
he  eyelid  margin  and  is  a  widely  used  treatment  in  the
anagement  of  both  blepharitis  and  meibomian  gland  dys-
unction  (MGD).11 Finally,  omega-3  fatty  acids  play  a  role  in
ry  eye  management  by  reducing  inﬂammation  at  the  ocular
urface.10
While  there  are  many  studies  that  show  improvement
ith  these  treatment  modalities,  there  are  very  few  that
xamine  the  effect  of  combined  therapy.  It  could  be  that
he  combination  therapy  effect  is  synergistic  and  provides
elief  greater  than  the  sum  of  each  single  therapy.  Alterna-
ively,  it  could  also  be  that  the  effect  of  combined  treatment
ay  have  a  ceiling  effect  and  that  the  addition  of  extra
roduct  may  yield  little  or  no  extra  relief.  Therefore,  the
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Table  1  Inclusion  and  exclusion  criteria  for  entry  into  study.
Inclusion  Exclusion
Between  18  and  70  years  old  Has  any  active  ocular  disease  (other  than  blepharitis,  MGD,
dry eye),  infection  or  allergies
Exhibits symptoms  of  dry  eye  for  at  least  3  months  Has  a  systemic  condition  or  taking  medications  that  may
affect a  study  outcome  variable
Ocular Surface  Disease  Index  (OSDI)  of  ≥23  Has  worn  contact  lenses  in  the  past  5  years
On a  dry  eye  regimen  that  consists  of  instilling  artiﬁcial  tears
at least  3  times  a  week  for  the  past  3  months
Is  currently  on,  or  have  used  omega  3  supplements  in  the
past 3  months
Has an  average  non-invasive  tear  breakup  time  (NIBUT)  of
≤5.00  s  in  at  least  one  eye
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iurpose  of  this  study  was  to  determine  the  effectiveness  of
ombined  therapy  of  a  lubricant  eye  drop  (Advanced  Vision
esearch  Inc,  TheraTears® Lubricant  Eye  Drop,* Ann  Arbor,
I,  USA),  eyelid  hygiene  (Advanced  Vision  Research  Inc,
heraTears® SteriLid,† Ann  Arbor,  MI,  USA),  and  oral  omega-
 supplements  (Advanced  Vision  Research  Inc,  TheraTears®
utrition,‡ Ann  Arbor,  MI,  USA),  on  the  relief  of  dry  eye  symp-
oms  and  signs  in  patients  with  moderate  to  severe  dry  eye
isease.
ethods
his  was  a  prospective  study  that  enrolled  28  dry  eye  partici-
ants.  The  key  inclusion  and  exclusion  criteria  are  outlined
n  Table  1.
The  study  was  conducted  at  the  Centre  for  Contact  Lens
esearch  (CCLR),  at  the  University  of  Waterloo  (UW).  The
tudy  was  conducted  in  conformance  with  the  ethical  prin-
iples  of  the  Declaration  of  Helsinki,  the  ICH  guidelines  for
ood  Clinical  Practice,  the  UW  Guidelines  for  Research  with
uman  Participants.  Informed  consent  was  obtained  from
ll  participants  prior  to  enrollment  in  the  study.  Ethics  clear-
nce  was  obtained  through  a  UW  Research  Ethics  Committee
rior  to  commencement  of  the  study.
All  participants  were  screened  at  the  baseline  visit  to
etermine  their  eligibility.  Once  eligibility  was  determined,
articipants  were  enrolled  and  baseline  measurements
ere  obtained.  Participants  were  then  asked  to  cease
heir  current  dry  eye  treatment  and  provided  with  the
heraTears® Lubricant  Eye  Drop,  TheraTears® SteriLid,  and
he  TheraTears® Nutrition  to  use,  as  per  label.  Details  about
he  study  products  can  be  found  in  Table  A.1.
After  leaving  the  CCLR  at  the  baseline  visit,  participants
ere  asked  to  start  using  the  products  immediately.  All  par-
icipants  were  contacted  at  2  weeks  into  the  study  to  ensure
hat  adherence  to  product  use  was  maintained,  to  monitor
dverse  events,  and  to  measure  symptoms.  All  participants
eturned  at  1  month  and  3  months  for  follow  up  measure-
ents.
∗ Advanced Vision Research Inc is now Akorn Consumer Health.
† In Canadian markets, SteriLid is marketed as TheraLid.
‡ TheraTears® Nutrition is now marketed as TheraTears® Eye
utrition.
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Alinical  measurements
t  the  beginning  of  each  study  visit,  adherence  to  product
nd  changes  to  health  or  medications  was  documented.
Symptoms  were  assessed  with  the  Ocular  Surface  Disease
ndex  (OSDI),15 and  the  Symptoms  Assessment  iN  Dry  Eye
SANDE).6 The  OSDI  is  a  dry  eye  questionnaire  that  quanti-
ed  dry  eye  symptoms  in  the  context  of  visual  symptoms,
isual  tasks,  and  environmental  factors.  The  SANDE  quanti-
ed  dry  eye  symptoms  by  combining  two  visual  analog  scales
hat  separately  assessed  frequency  and  severity  of  dry  eye
ymptoms.6
Tear  osmolarity  was  conducted  using  the  TearLabTM
smolarity  System  (TearLabTM,  CA,  USA).16 Prior  to  testing,
articipants  veriﬁed  that  no  eye  drops  were  instilled  2 h
rior  to  arriving  at  the  visit.  The  tip  of  the  pen  was  gently
ouched  to  the  tear  meniscus  on  the  temporal  lid  margin  to
btain  a  reading,  as  per  manufacturer  recommendation.
The  tear  ﬁlm  lipid  layer  thickness  (LLT)  was  assessed  using
he  LipiView  (TearScience®, North  Carolina,  USA)  in  primary
aze.17 The  average  interferometric  color  unit  (ICU)  for  each
ye  was  documented.
Tear  meniscus  height  was  measured  to  0.01  mm  accu-
acy  using  the  Keratograph® 5M  (OCULUS  Inc,  Wetzlar,
ermany).18 The  built-in  software  ruler  was  used  to  con-
uct  the  measurement.  The  ruler  was  drawn  from  edge  of
he  tear  meniscus  at  the  6  o’clock  position  of  the  pupil  ver-
ically  downward  to  the  edge  of  the  eyelid  margin.  This  was
onducted  3  times  and  the  values  were  averaged.
Non-invasive  tear  breakup  time  was  conducted  by  using  a
orneal  topographer.19 An  illuminated  placido  disc  was  pro-
ected  onto  the  cornea  and  imaged  with  an  infrared  CCD
amera  in  the  Humphrey  Atlas® Topographer  991  (Zeiss,  CA,
SA).  This  was  conducted  by  asking  participants  to  hold  their
yes  open  for  as  long  as  they  could.  A stopwatch  was  used
o  quantify  the  time  in  which  distortions  began  to  appear
n  the  reﬂected  placido  disc.  This  measurement  was  mea-
ured  to  0.01  s  accuracy,  and  repeated  three  times  and  then
veraged.
Eyelid  margin  features  were  examined  under  a  slit  lamp.
he  parameters  of  interest  were  erythema,  edema,  vas-
ularity  and  telangiectasia.  They  were  each  graded  and
ummed  to  generate  a  composite  eyelid  margin  score.  The
rading  scale  used  for  each  parameter  is  outlined  in  Table
.2.
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Table  2  Summary  of  procedures  and  instruments.
Testing
order
Procedure  Instrument
1  Compliance  and  adverse  event  check  N/A
2 Symptoms  assessment  OSDI  and  SANDE
3 Entrance  visual  acuity  Electronic  logMAR  chart
4 Osmolarity  TearLab  Osmolarity  System
5 LLT  LipiView
6 Tear  meniscus  height  Keratograph® 5M
7 NIBUT  Atlas® topographer
8 Eyelid  margin  features
Slit  lamp,
ﬂuorescein  and
Lissamine  green.
9 Corneal  staining,  conjunctival  staining
10 LWE
11 MG  function  (meibum  quality,  expressibility,  #  glands  blocked)
12 Meibography  Keratograph® 5M
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313 Schirmer’s  test  
14 Exit  visual  acuity  
A  strip  of  ﬂuorescein  was  wetted  with  a  few  drops  of
saline,  and  was  instilled  in  each  eye  to  assess  corneal  stain-
ing.  Corneal  staining  was  assessed  using  the  CCLR  scale,
which  assessed  type,  depth,  and  extent  of  staining  on  a
scale  of  0--100  each.20 After  1  min  had  elapsed,  ﬂuorescein
was  instilled  once  more.  After  waiting  for  another  3  min,  the
superior  eyelid  was  everted  and  ﬂuorescein  lid  wiper  epithe-
liopathy  (LWE)  was  assessed.21 A  strip  of  Lissamine  green  was
wetted  with  a  few  drops  of  saline  and  instilled  into  both  eyes
to  assess  conjunctival  staining  (using  the  Oxford  Scale).22
After  1  min,  Lissamine  green  was  instilled  again.  The  eye-
lids  were  everted  after  3  min  to  assess  Lissamine  green  LWE.
Both  ﬂuorescein  and  Lissamine  green  LWE  grades  were  aver-
aged  to  generate  the  ﬁnal  LWE  grade.21 Table  A.3  outlines
further  details  on  LWE  grading.
Meibomian  gland  function  was  assessed  by  observing  the
expressibility  and  quality  of  meibum  in  the  inferior  cen-
tral  8  glands.  Meibomian  gland  expressibility  was  assessed
by  applying  variable  digital  pressure  to  the  lid  margin  and
estimating  the  force  required  to  express  meibum.  Meibum
quality  was  then  assessed  by  applying  ﬁrm  digital  pressure  to
the  lid  margin  and  assessing  the  physical  characteristics  of
meibum  using  a  4  point  grading  scale  previously  described.23
The  number  of  blocked  glands  (out  of  8)  were  deﬁned  as  ones
that  did  not  express  liquid  secretions.
Meibography  was  assessed  by  everting  the  lower  and
upper  eyelids  and  imaging  the  tarsal  plate  using  the
Keratograph® 5M.24 The  amount  of  MG  dropout  from  the
upper  and  lower  eyelids  were  was  quantiﬁed  using  a  grading
scale  previously  described,25 and  summed.
Schirmer’s  test  was  conducted  by  inserting  a  Schirmer
strip  for  5  min  in  the  lateral  1/3  of  the  eyelid  margin.  Par-
ticipants’  eyes  were  closed  for  the  duration  of  5  min.  The
amount  of  wetting  after  this  duration  was  quantiﬁed.
A  summary  of  clinical  testing  and  the  order  in  which  they
were  conducted  is  summarized  in  Table  2.Statistical  analysis
Statistical  analysis  was  conducted  using  GraphPad  Prism  6.05
(GraphPad  Software,  CA,  USA).
C
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sSchirmer’s  strips
Electronic  logMAR  chart
Normal  data  distribution  testing  was  conducted  using  the
hapiro--Wilk  normality  test.  Repeated  Measures  ANOVA  was
onducted  on  variables  that  had  passed  the  normality  test
ith  a  threshold  of  alpha  =  0.05.  Post  hoc  Dunnett’s  test
as  used  to  determine  which  visit  was  signiﬁcantly  different
rom  baseline  values  in  parametric  distributions.  Friedman
est  was  conducted  on  non-parametric  variables  that  did  not
ass  the  normality  test.  Dunn’s  test  was  used  to  determine
hich  visits  were  signiﬁcantly  different  from  other  visits  in
on-parametric  distributions.
Data  from  only  the  left  eye  was  analyzed.  Threshold  for
tatistical  signiﬁcance  was  taken  when  p  <  0.05.
esults
articipants
 total  of  20  participants  (17  female,  3  male)  completed
he  study.  The  mean  age  of  the  participants  was  43  (median
1  years,  ranging  from  23  to  66  years).  All  participants  had
reviously  used  lubricant  eye  drops  for  at  least  once  a  day
efore  switching  over  to  the  study  products.  Participants
ere  not  on  any  dry  eye  medications  (e.g.  cyclosporine,
teroids)  and  were  not  using  any  eyelid  hygiene  products
t  the  time.  With  a  combination  of  OSDI  ≥  23,  NIBUT  <  5.0  s,
igniﬁcantly  altered  meibum  quality  and  gland  obstruction
t  baseline  (Table  3),  participants  in  this  sample  appeared
o  have  moderate  to  severe  dry  eye.
ompliance
articipant  adherence  to  product  usage  was  monitored  at
very  visit.  On  average,  participants  had  used  the  Lubricant
ye  Drops  2.4×  per  day,  SteriLid  1.1×  per  day,  and  Nutrition
 gel  caps  once  daily.linical  ﬁndings
here  was  a  signiﬁcant  improvement  in  symptoms  as  mea-
ured  by  the  OSDI  (Fig.  1).  The  net  change  from  baseline
30  W.  Ngo  et  al.
Table  3  Summary  of  clinical  changes  over  time  (n  =  20).
Ocular  measurement  Baseline  2  weeks  1  month  3  month  p-Value
Parametric  (mean  ±  SD)
OSDI  44.8  ±  17.0  25.0  ±  15.6* 23.4  ±  15.1* 23.6  ±  17.9* <0.01
SANDE Global  Score  63.0  ±  20.6  52.8  ±  23.2* 41.6  ±  27.3* 30.6  ±  25.1* <0.01
Eyelid margin  score  6.0  ±  3.1  N/A  5.6  ±  2.7  4.9  ±  2.6* 0.02
LLT 82.2  ±  15.4  N/A  76.6  ±  15.9  79.5  ±  16.7  0.21
Osmolarity 301  ±  13  N/A  304  ±  11  302  ±  11  0.35
Non-parametric  (Q1,  median,  Q3)
NIBUTa 1.75,  2.42,  3.27 N/A  1.97,  3.05,  4.49* 2.22,  2.90,  3.63* 0.02
Meibum qualitya 2.0,  2.5,  3.0 N/A  2.0,  2.0,  2.0 1.0,  1.5,  2.0* <0.01
Expressibilitya 2.0,  2.0,  3.0 N/A  1.0,  2.0,  2.0 1.0,  2.0,  2.0* <0.01
Number of  glands  blockeda 5.3,  6.0,  7.0  N/A  2.3,  4.0,  6.0* 1.0,  2.0,  4.8* <0.01
Schirmer’s testa 4.5,  8.5,  14.0  N/A  4.0,  9.0,  13.0  5.3,  11.0,  25.0  0.41
Meniscus Heighta 0.17,  0.20,  0.26  N/A  0.16,  0.19,  0.27  0.18,  0.22,  0.24  0.78
LWEa 0.00,  0.00,  0.19  N/A  0.00,  0.00,  0.75  0.00,  0.00,  0.50  0.29
Corneal Staininga 14,  53,  96  N/A  5,  40,  124  3,  25,  46  0.36
Conjunctival  Staininga 0.2,  1.0,  2.0  N/A  0.0,  1.0,  1.0  0.0,  1.0,  1.0  0.08
Meibographya 0.2,  2.0,  4.0  N/A  1.0,  2.0,  3.8  1.0,  2.0,  4.0  0.66
a Friedman test.
* p < 0.05 from baseline.
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Figure  2  NIBUT  signiﬁcantly  improved  over  the  course  of  the
study, with  a  total  net  change  of  +0.48  s  at  3  months.
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vigure  1  The  OSDI  score  showed  signiﬁcant  change  over  time,
ith a  total  net  change  of  −21.2  points  over  the  study  duration.
o  week  2  (−19.8),  to  1  month  (−21.4),  and  to  3  months
−21.2)  was  all  statistically  signiﬁcant  (all  p  <  0.01).  There
as  also  a  signiﬁcant  improvement  in  SANDE  scores.  The
et  change  at  week  2  (−10.2),  at  1  month  (−21.4),  and  at
 months  (−32.4)  was  all  statistically  signiﬁcant  from  base-
ine  (all  p  <  0.01).
NIBUT  was  signiﬁcantly  improved  from  baseline.  A
edian  improvement  of  +0.63  s  at  1  month  and  +0.48  s  at
 months  was  both  statistically  signiﬁcant  (both  p  <  0.05)
ig.  2.
Eyelid  margin  scores  showed  signiﬁcant  change  over  the
ourse  of  the  3  months  (Fig.  3).  Although  the  change  from
aseline  to  1 month  was  not  statistically  signiﬁcant  (−0.4
rade  units,  p  >  0.05),  the  change  from  baseline  to  3  month
as  signiﬁcant  (−1.1  grade  units,  p  <  0.05).
Meibomian  gland  function  was  also  observed  to  improve
igniﬁcantly  (Fig.  4).  Meibum  quality  was  not  signiﬁcantly
ifferent  than  baseline  at  1  month,  but  became  signiﬁcantly
ifferent  at  3  months  (−0.5  grade  units,  p  =  0.16;  −1.0  grade
nits,  p  =  0.01,  respectively).  The  number  of  glands  blocked
lso  reduced  signiﬁcantly  from  baseline  to  1  month  (−2.0
lands,  p  =  0.04),  and  to  3  months  (−4.0  glands,  p  <  0.01).
c
f
rigure  3  Eyelid  margin  features  gradually  improved  over  the
ourse  of  the  3  months,  with  a  signiﬁcant  net  change  in  of  −1.1
rade  units  from  baseline.
There  was  no  signiﬁcant  difference  in  Schirmer’s  test,
LT,  tear  meniscus  height,  LWE,  corneal  staining,  conjuncti-
al  staining,  meibography,  and  osmolarity.  A  summary  of  the
linical  results  is  listed  in  Table  3.
A  total  of  8  participants  were  prematurely  discontinued
rom  the  study.  There  were  2  participants  who  had  expe-
ienced  adverse  events  related  to  study  product  use.  One
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Figure  4  Summary  of  changes  to  MG  function  over  the  course  of  the  study.  By  the  end  of  3  months  there  was  a  signiﬁcant
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aimprovement  from  baseline  in  meibum  quality,  number  of  MGs  
participant  experienced  dyspepsia  after  ingesting  the  Nutri-
tion  gel  caps,  and  the  other  participant  felt  signiﬁcant  eyelid
discomfort  after  using  the  SteriLid.  These  symptoms  were
resolved  upon  cessation  of  the  study  product.  The  remaining
6  participants  were  found  to  be  ineligible  at  screening.  The
data  from  these  participants  were  not  used  in  the  analysis.
Discussion
This  study  showed  that  a  combination  of  lubricant  eye  drops,
lid  hygiene,  and  oral  omega-3  supplements  was  effective  in
improving  moderate  to  severe  dry  eye.
Because  of  the  study  design,  it  is  not  possible  to  deter-
mine  from  the  data  how  much  each  separate  component
contributed  to  the  improvement  in  dry  eye.  Due  to  dif-
ferences  in  clinical  testing  and  grading  scales  it  is  also
very  difﬁcult  to  compare  results  to  other  published  stud-
ies.  For  example,  the  oral  omega-3  supplements  used  in  this
study  (450  mg  eicosapentaenoic  acid  (EPA)/300  mg  docosa-
hexaenoic  acid  (DHA)/450  mg  alpha  linolenic  acid  (ALA),
total  omega-3  content  of  1200  mg  daily)  have  been  shown
to  be  effective  in  reducing  dry  eye  symptoms,26,27 however
the  methods  for  symptoms  assessment  or  reporting  were  dif-
ferent  from  this  study.  Two  previous  studies  reporting  OSDI
outcomes  using  oral  omega-3  supplements  showed  that  OSDI
scores  improved  by  11.6  units  (participants  taking  6000  mg
ﬂaxseed  oil  daily),28 and  8.3  units  in  a  separate  study  (par-
ticipants  taking  360  mg  EPA,  240  DHA  daily).29
The  scenario  is  similar  for  the  lubricant  eye  drop  and  the
eyelid  hygiene  product  used  in  this  study.  This  is  the  ﬁrst
clinical  study  documenting  the  effectiveness  in  relieving
symptoms  using  the  TheraTears® lubricant  eye  drop  in
conjunction  with  other  dry  eye  treatments.  However,  there
are  no  studies  with  TheraTears® lubricant  eye  drops  as
a  stand-alone  product  documenting  symptom  relief.  In
other  studies  that  have  reported  OSDI  outcomes  with  other
artiﬁcial  tears,  one  had  reported  a  change  of  approxi-
mately  14.0  units  with  three  separate  artiﬁcial  tear  drops
formulations  (used  2--3  times  daily)  each,30 and  another
study  showed  that  OSDI  improved  by  approximately  13  units
with  4  different  formulations  (used  3  times  daily)  each.31
Similarly,  the  only  study  that  reported  an  OSDI  outcome
with  an  eyelid  hygiene  product  (Blephaclean  twice  a  day)
showed  an  improvement  of  10  units.12
If  we  follow  the  assumption  that  artiﬁcial  tears,  eyelid
hygiene,  and  omega-3  supplements  provide  an  improvement
s
a
aed,  and  expressibility  of  glands  (all  p  <  0.05).
o  OSDI  of  13,  10,  and  10  points  respectively,  then  a
omplete  additive  effect  of  combined  therapy  would  yield
 theoretical  improvement  of  33  points  to  the  OSDI.  How-
ver,  the  differences  between  reported  therapy  ingredients,
uration  of  therapy,  dosage,  population  sampling,  and  study
esign  make  it  very  difﬁcult  to  estimate  the  true  poten-
ial  improvement  for  OSDI  scores  and  it  is  unlikely  that
hese  beneﬁts  are  summative  in  this  manner.  The  total
mprovement  in  OSDI  score  in  this  study  (21.2)  suggests  that
ombination  therapy  is  approximately  twice  as  effective  as
eported  single  therapies  in  relieving  symptoms.  Although
e  have  not  examined  the  effectiveness  of  the  single  ther-
pies  in  this  combination,  it  is  unlikely  that  any  single  one
roduct  here  could  be  responsible  for  an  improvement  in
SDI  of  this  magnitude.  Therefore,  an  additive  effect  from
t  least  two  of  the  therapies  is  likely  the  case.
The  improvement  in  eyelid  margin  scores  suggests  that
he  combination  therapy  had  an  effect  in  relieving  ble-
haritis.  The  decrease  in  clinical  inﬂammation  can  likely
e  attributed  to  the  actions  of  the  oral  omega-3  supple-
ents,  eyelid  hygiene,  and  even  the  lubricant  eye  drops.
ral  omega-3  supplements  have  been  studied  extensively
nd  have  been  shown  to  reduce  inﬂammatory  biomarkers
n  the  body.32 The  antimicrobial  activity  of  SteriLid  against
he  eyelid  bacteria  strains  have  previously  been  studied
n  vitro  (and  compared  with  povidone  iodine).13 A  combi-
ation  of  omega-3  supplements  and  eyelid  hygiene  together
ave  been  previously  studied,33 and  have  shown  improve-
ents  in  tear  break  up  time,  MG  expression,  eyelid  margin
nﬂammation,  and  symptomatic  relief.  These  ﬁndings  are
irrored  very  well  by  our  study,  as  we  also  found  signiﬁcant
mprovements  in  MG  function,  tear  breakup  time,  eyelid
argin  inﬂammation  and  symptoms.
Despite  improvements  in  MG  function,  there  was  no  sig-
iﬁcant  change  in  gland  atrophy  (meibography)  over  time.
his  was  an  expected  ﬁnding,  as  MG  atrophy  occurs  at  a
ery  slow  rate  and  may  take  many  years  for  any  change  to
e  detectable.  A  previous  study  by  Arita  et  al.25 document-
ng  the  prevalence  of  age-related  MG  atrophy  showed  that
hanges  to  MG  atrophy  can  take  decades  to  occur.  Therefore,
ny  change  (if  present)  could  not  have  been  detected  within
he  course  of  this  study.  However,  it  would  be  helpful  to  run
 prospective  longitudinal  study  spanning  several  years  to
ee  whether  or  not  adding  an  intervention  can  impact  gland
trophy  rates.
This  study  was  not  able  to  detect  any  changes  in  corneal
nd  conjunctival  staining.  The  low  amounts  of  corneal  and
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onjunctival  staining  presenting  at  baseline  could  be  due
o  the  fact  that  participants  were  already  on  drops  when
hey  presented  for  this  study.  Any  improvement  (if  present)
rom  the  treatment  effect  would  have  been  very  small,  and
herefore  hard  to  detect.  For  future  reference,  it  may  be  a
ood  idea  to  consider  having  participants  go  on  a  ‘‘washout’’
eriod  prior  to  beginning  a  study  such  as  this,  to  allow  them
o  manifest  their  full  corneal  and  conjunctival  staining  at
aseline.
Osmolarity  also  did  not  change  throughout  the  study
eriod.  Osmolarity  is  considered  to  be  a  complex  aspect
f  dry  eye  disease  involving  the  breakdown  of  homeostatic
echanisms.34 Similar  to  some  of  the  other  measures,  the
smolarity  readings  may  have  been  impacted  by  the  partici-
ants  presenting  at  baseline  already  on  drops.  A  ‘‘washout’’
eriod  prior  to  the  baseline  osmolarity  reading  would  have
een  expected  to  provide  higher  initial  readings.  The  2007
ry  Eye  Workshop  deﬁnes  dry  eye  as  high  osmolarity  readings
or  participants  with  dry  eye.1 It  would  be  expected  that
hose  participants  with  high  osmolarity  readings  using  the
ubricant  eye  drop  in  this  study  containing  a  hypo-osmolarity
omponent  would  have  decreased  osmolarity  over  time.  A
revious  study  showed  that  higher  variability  was  attributed
o  blepharitis  and  Sjögren’s  syndrome  dry  eye  compared  to
ormals.35 In  our  study,  we  had  found  that  the  standard
eviations  in  our  osmolarity  measurements  remained  sim-
lar  over  time  (12.6  at  baseline,  11.1  at  1  month,  11.1  at
 months)  even  though  we  observed  improvements  in  many
ther  areas  (e.g.  OSDI,  NIBUT,  eyelid  margin  scores).  One
ossible  reason  for  this  is  that  participants  in  this  sample
id  not  exhibit  high  osmolarity  to  begin  with,  therefore  mak-
ng  it  appear  that  undergoing  treatment  had  no  effect  over
ime.
A  limitation  of  this  study  was  that  since  there  were  no
lacebo  controls,  a  placebo  effect  may  be  present  and  can-
ot  be  ruled  out.  For  future  work,  implementation  of  an
ndependent  control  group  would  help  us  better  understand
he  ﬁndings  in  this  study.
onclusion
he  combined  therapy  of  TheraTears® Lubricant  Eye  Drops,
heraTears® SteriLid,  and  TheraTears® Nutrition  improved
oth  symptoms  and  a  variety  of  signs  in  participants  with
oderate  to  severe  dry  eye.
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